Backed by ARCH Venture Partners, F-Prime Capital and Mubadala Capital, the new company will develop a pipeline of ...

Tenvie Therapeutics has unveiled with $200 million and the goal of transforming the neurological treatment landscape, nabbing ...

1,2 BIIB122 (DNL151) is a selective, central nervous system-penetrant small molecule inhibitor of LRRK2 that is hypothesized to improve lysosomal dysfunction. Denali’s strategic partner Biogen ...

Advancing a deep pipeline of therapeutics focused on treating neurological, cardiometabolic, and ophthalmic diseasesLed by expert R&D ...

1,2 BIIB122 (DNL151) is a selective, central nervous system-penetrant small molecule inhibitor of LRRK2 that is hypothesized to improve lysosomal dysfunction. Denali’s strategic partner Biogen is ...

Pathogenic mutations in LRRK2 account for 4-5% of familial and 1-2% of sporadic Parkinson’s disease. 1,2 BIIB122 (DNL151) is a selective, central nervous system-penetrant small molecule inhibitor of ...